Medical/Pharmaceuticals
Luye Pharma's Rivastigmine Twice Weekly Transdermal Patch Approved for Marketing in Japan for the Treatment of Alzheimer's Dementia
TOKYO, March 31, 2025 /PRNewswire/ -- Luye Pharma Group today announced that marketing approval for its innovative formulation Rivastigmine Twice Weekly Transdermal Patch has been granted by the Japanese Ministry of Health, Labour and Welfare as a new drug, indicated for suppression of progressio...
2025-03-31 21:35
2924
Lunit Announces Partnership with the National Cancer Institute to Advance AI-Powered Biomarker Research
Collaboration to apply Lunit's AI technologies across NCI's broad spectrum of cancer studies, aiming to accelerate personalized cancer care SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Lunit (KRX:328130.KQ), a leading provider of AI-powered solutions for cancer diagnostics and therapeutics...
2025-03-31 21:00
2366
Ascletis Announces Positive Interim Results from Its U.S. Phase Ib Trial with ASC30, a Potentially First-in-Class Subcutaneous Injection Small Molecule GLP-1R Agonist
-Ultra-long-acting subcutaneous (SQ) injection formulation of small molecule ASC30 demonstrated a 36-day half-life in patients with obesity, supporting once monthly or less frequent administration. -As previously disclosed, oral tablet formulation of small molecule ASC30 demonstrated potentially ...
2025-03-31 19:00
2517
Harbour BioMed Reports Full Year 2024 Financial Results
CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SHANGHAI, March 31, 2025 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunology and oncology, today announced its ...
2025-03-31 18:13
3344
Clinical Study demonstrates Kerry Group Supplement Solution Sensoril® Ashwagandha Supports Quality of Life for Post-Menopausal Women
Sensoril® Ashwagandha is among Kerry's portfolio of solutions tailored to meet
women's unique health needs
SINGAPORE, March 31, 2025 /PRNewswire/ -- Sensoril® ashwagandha
2025-03-31 17:30
2917
Revenue Soars 44%, Basecare Medical (2170.HK) Advances Toward Global Intelligent Manufacturing
SUZHOU, China, March 31, 2025 /PRNewswire/ -- Amid frequent pro-fertility policy updates, Basecare Medical, a pioneer in the assisted reproductive IVD sector with full fertility health industry chain coverage, released its stellar 2024 performance report. The company achieved annual revenue of ne...
2025-03-31 17:01
4195
Reaffirming Leadership: Medit's Strong Presence at IDS 2025
COLOGNE, Germany and SEOUL, South Korea, March 31, 2025 /PRNewswire/ -- Medit, a global leader in digital dentistry solutions, made a significant impact at International Dental (IDS) 2025 by unveiling its latest innovations in intraoral scanning and comprehensive digital workflows. Alongside new ...
2025-03-31 15:00
2905
S Spine Hospital Launches T-Shirt to Raise Awareness About Back Pain
BANGKOK, March 31, 2025 /PRNewswire/ -- S Spine Hospital, a specialist in
spine, has unveiled "THE SPINE T-SHIRT," a health communication initiative
designed to transform how people perceive and understand spinal health issues.
2025-03-31 14:52
1871
Ceva Animal Health renews its shareholding structure with all its long-standing partners and opens its capital to Mérieux Institute and ARCHIMED to accelerate its growth.
LIBOURNE, France, March 31, 2025 /PRNewswire/ -- Ceva Animal Health
2025-03-31 14:12
3022
Acer Medical Debuts VeriSee AI-assisted Screening Solutions at the Malaysian Ophthalmology Society Annual Congress
Collaboration with Intel® for AI-powered medical screening optimizations TAIPEI, March 31, 2025 /PRNewswire/ -- Acer Medical has recently launched its AI-assisted screening software, VeriSee Diabetic Retinopathy and VeriSee Age-Related Macular Degeneration. These innovative solutions will be show...
2025-03-31 11:32
2744
Smartee Pioneers a New Phase in Orthodontics with Silicon Valley Founder Mode
SHANGHAI, March 30, 2025 /PRNewswire/ -- As the clear aligner business enters the second quarter of 2025, it shows a promising growth trend. With increasing competition and innovation in the market, Smartee Denti-Technology remains committed to its "Founder Mode," aiming to seize new business opp...
2025-03-31 10:59
2321
Innovent Receives NMPA Breakthrough Therapy Designation for IBI363 (PD-1/IL-2α-bias Bispecific Antibody Fusion Protein) in Melanoma
SAN FRANCISCO and SUZHOU, China, March 31, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmun...
2025-03-31 09:22
3054
Human Frontier Science Program: Fellowships Awarded to 60 Pioneering Postdoctoral Scientists from 25 Nations
STRASBOURG, France, March 31, 2025 /PRNewswire/ -- To foster the next
generation of life science research, 60 of the world's top emerging scientists
from 25 nations have won 2025 Human Frontier Science Program (HFSP) Fellowships.
2025-03-31 08:00
2040
AIM Vaccine reduces losses by nearly 90% in 2024, with the iterative major product series opening up space for explosive growth in performance
HONG KONG, March 31, 2025 /PRNewswire/ -- AIM Vaccine Co., Ltd. (06660.HK), a leading PRC vaccine company, published its 2024 Annual Results announcement on March 30, 2025, the company recorded revenues of RMB 1,285 million in 2024, an increase of 8.2% compared to the previous year, with significa...
2025-03-31 08:00
3596
Akeso's 2024 Results: Strengthening Global Competitiveness and Transforming the Treatment Landscape with Bispecific Antibodies
Key Highlights: * Global first "immuno + anti-vascular" bispecific antibody approved: ivonescimab for EGFR-TKI resistant nsq-NSCLC. Phase III HARMONi study topline data expected mid-2025 (FDA FTD). * ivonescimab outperforms pembrolizumab in Phase III study for first-line PD-L1+ NSCLC: mPFS H...
2025-03-31 02:32
3475
Fosun International Announces 2024 Annual Results: Total Revenue Reaches RMB192.14 Billion, Industrial Operation Profit Amounts to RMB4.9 Billion, Overall Operational Fundamentals Remain Stable
2024 Annual Results Highlights: * Total revenue reached RMB192.14 billion; * Industrial operation profit amounted to RMB4.9 billion; * Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's total revenue; * Total debt to tot...
2025-03-30 21:54
3995
Brii Bio Unveils New Data from Its Ongoing Phase 2 ENSURE Study at APASL 2025, Showcasing BRII-179's Unique Potential to Prime and Boost Higher HBsAg Loss Through Target Patient Identification
* Preliminary data from Cohort 4 of the ENSURE study supports a novel enrichment strategy to utilize BRII-179 to identify patients who are immune responders and have the potential to achieve higher HBsAg loss at EOT * 48-week EOT data from Cohort 1-3 of the ENSURE study clearly suggests the a...
2025-03-30 19:10
4671
LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%
SHENZHEN, China, March 30, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiari...
2025-03-30 01:02
4829
Zylox-Tonbridge Announces 2024 Annual Results: Achieves Full-Year Profit for the First Time with Net Profit Exceeding USD 14 Million
HANGZHOU, China, March 28, 2025 /PRNewswire/ -- On March 20, Zylox-Tonbridge Medical Technology Co., Ltd. (Stock Code: 2190.HK, hereinafter referred to as "Zylox-Tonbridge" or the "Company") released its 2024 annual results. In 2024, the Company reported revenue ofUSD 109.4 million, a year-on-yea...
2025-03-29 11:53
6002
LifeTech Scientific Corporation Announced 2024 Annual Results: Revenue Exceeded RMB1.3 billion, and International Business Increased by 26%
SHENZHEN, China, March 28, 2025 /PRNewswire/ -- LifeTech Scientific Corporation (the "Company" or "LifeTech", Stock code: 1302.HK), a company specializing in minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases, together with its subsidiari...
2025-03-29 01:24
5652
Week's Top Stories
Most Reposted
Edufrienz 99: One of Asia's First Digital Platform Advancing Character Education for Future-Ready, Compassionate Children
[Picked up by 319 media titles]
2026-01-23 11:03
Agoda Launches Agoda Impact Lab at ASEAN Tourism Forum
[Picked up by 310 media titles]
2026-01-29 15:06
Agoda Launches Open-Source API Agent to Simplify MCP Server Integrations
[Picked up by 309 media titles]
2026-01-27 13:00
UOB prices AUD2 billion in five-year senior unsecured notes
[Picked up by 307 media titles]
2026-01-23 09:00Nokia Strengthens Edge AI Capabilities Through Strategic Collaboration with Blaize on Hybrid Inference Solutions Across Asia Pacific Regions
[Picked up by 294 media titles]
2026-01-27 18:00
Most Read
ATOTO CB7 Pro 301% Funded--Head‑Unit AI Console for Wireless CarPlay/Android Auto and Camera‑Smart Driving
2026-01-23 23:00
8142
